Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma
- Authors
- Kim, Yuna; Lee, Han Ah; Lee, Jae Seung; Jeon, Mi Young; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Um, Soon Ho; Seo, Yeon Seok; Kim, Seung Up
- Issue Date
- 16-3월-2021
- Publisher
- TAYLOR & FRANCIS INC
- Keywords
- TARE; Yttrium-90; curative treatment; hepatocellular carcinoma; radioembolization
- Citation
- CANCER INVESTIGATION, v.39, no.3, pp.274 - 283
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER INVESTIGATION
- Volume
- 39
- Number
- 3
- Start Page
- 274
- End Page
- 283
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/137736
- DOI
- 10.1080/07357907.2020.1870126
- ISSN
- 0735-7907
- Abstract
- Transarterial radioembolization (TARE) is one of the therapeutic options for hepatocellular carcinoma (HCC). This study aimed to investigate the predictors and prognostic values of achieving curative treatments after TARE. Overall, 143 patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited from two Korean tertiary institutes. Twenty-seven patients received curative treatments after TARE. Younger age than 65 years and AFP of <= 200 ng/mL independently predicted the increased probability of achieving curative treatment after TARE, and the curative treatment after TARE provided a survival benefit in patients with intrahepatic HCC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.